Ignoring Gender-Based Immunometabolic Reprograming, a Risky Business in Immune-Based Precision Medicine

Vijay Kumar

Frontiers in Bioscience-Landmark ›› 2025, Vol. 30 ›› Issue (1) : 27118

PDF (1549KB)
Frontiers in Bioscience-Landmark ›› 2025, Vol. 30 ›› Issue (1) :27118 DOI: 10.31083/FBL27118
Opinion
other
Ignoring Gender-Based Immunometabolic Reprograming, a Risky Business in Immune-Based Precision Medicine
Author information +
History +
PDF (1549KB)

Abstract

Immunology advances have increased our understanding of autoimmune, auto-inflammatory, immunodeficiency, infectious, and other immune-mediated inflammatory diseases (IMIDs). Furthermore, evidence is growing for the immune involvement in aging, metabolic and neurodegenerative diseases, and different cancers. However, further research has indicated sex/gender-based immune differences, which further increase higher incidences of various autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), myasthenia gravis, and rheumatoid arthritis (RA) in females. On the other hand, reproductive-age females also show a more potent immune response against infections and vaccines than their age-matched males—furthermore, some immune-based therapies, including immune checkpoint inhibitors (ICIs), show gender-based efficacy and adverse events. Metabolic demands are different in males and females. Immune cell function and polarization are also governed by their metabolic reprogramming, called immunometabolism and immunometabolic reprogramming (IR). Therefore, sex/gender-associated immune differences and their involvement in immune-mediated diseases and immune-based therapeutics indicate the demand for gender-based IR studies to increase the efficacy of immune-based precision medicine.

Graphical abstract

Keywords

sex/gender / immunometabolism / immunometabolic reprograming / immune cells / PRRs

Cite this article

Download citation ▾
Vijay Kumar. Ignoring Gender-Based Immunometabolic Reprograming, a Risky Business in Immune-Based Precision Medicine. Frontiers in Bioscience-Landmark, 2025, 30(1): 27118 DOI:10.31083/FBL27118

登录浏览全文

4963

注册一个新账户 忘记密码

1. Introduction

The use of immune-based therapies, such as vaccines, immune-checkpoint inhibitors (ICIs), and antibody- and cell-based immune therapies to prevent and treat infectious diseases, cancers, autoimmune and immunodeficiency disorders, and immune-mediated inflammatory diseases (IMIDs) has increased, indicating immunological advances in the disease management. However, along with several other factors, gender/sex is a critical factor for their efficacy and adverse events as sex hormones, along with X chromosome dosage compensation, critically impact immune functioning. The effective immune responses and immune cell polarization to pro-inflammatory, anti-inflammatory, and immunoregulatory phenotypes are critically regulated by the immune cell metabolism, called immunometabolism. The immunometabolism can be categorized into cellular and tissue immunometabolism and systemic immunometabolism. Therefore, gender-based immune differences, including immunometabolism and its reprogramming, must be in mind for immune-based precision medicine.

2. Evolution of Sex Chromosomes Needed an Immunological Inert Environment

Immune response has evolved to protect the host from internal and external threats. The immune system is classified into innate and adaptive immunity. The innate immune system is the most primitive form of the immune response, which is non-specific and very robust. The signaling components of innate immunity called pattern recognition receptors (PRRs), such as cytosolic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS)-like receptors (cGLRs) comprising vertebrate cGAS/stimulator of interferon gene (STING) signaling pathway are evolutionarily most ancient and have evolved in bacteria as a defense against bacteriophages at least 600 million years ago (MYA) (Fig. 1) [1, 2]. At the same time, the adaptive immunity evolved 500 MYA with the evolution of jawed vertebrates (gnathostomes) [3]. However, now we know that the oldest known animal sex chromosome, called Octopus-Z, has evolved in octopuses 380 MYA (Fig. 1) [4]. Thus, from an evolutionary perspective, the immune system evolved before the evolution of animal sex chromosomes, determining animal sex for sexual reproduction.

Furthermore, the localization of sex and other somatic chromosomes inside the nucleus prevents their immune recognition. However, genetic stress seen during infections and other inflammatory insults releases free DNA into the cytosol, which initiates a PRR-dependent pro-inflammatory immune response [5]. Thus, the location of the sex chromosome (inside the nucleus, which provides an immunologically inert site for intact DNA and chromosomes) indicates that the evolution of sex might have required an immune escape. We need further studies to investigate the evolutionary relationship between sex, sex chromosomes, and immunity. For example, cGAS, a potent PRR for double-stranded DNA (dsDNA) comprising cGLRs, is present in the nucleus but remains inactive due to its binding to nucleosomes and continuous competition with chromatin architectural components [6, 7, 8].

Furthermore, the ubiquitin-proteasome system (UPS) degrades nuclear cGAS in cells undergoing cell cycling signaling events SplA/Ryanodine Receptor Domain And SOCS Box Containing 3 (SPSB3) as the cGAS-targeting substrate receptor associates with the cullin—RING ubiquitin ligase 5 (CRL5) complex to ligate ubiquitin onto nuclear cGAS [9]. Notably, free or soluble cGAS can only recognize the virus and host-derived naked DNA to initiate the pro-inflammatory innate immune response. Interestingly, the soluble nuclear cGAS (cGAS not attached to the nucleosome or the chromatin) generated during viral infections, such as herpes simplex virus-1 (HSV-1), recognizes viral DNA, generates cyclic guanosine monophosphate (GMP)- adenosine monophosphate (AMP) (cGAMP), and type-1interferon (IFN)-dependent pro-inflammatory immune response [10]. Hence, the nucleus serves as a better place for chromosomes, including the sex chromosome, for their cellular localization, which is an immunologically inert location. However, evolutionarily, the cGAS system evolved first in the bacteria as cGAS-DncV (dinucleotide cyclase in Vibrio cholerae)-like nucleotidyltransferase (cyclic dinucleotidyltransferase (CD-NTase), a structurally and evolutionarily distinct subset of the DNA polymerase β-like nucleotidyltransferase superfamily) first reported in the Vibrio cholerae as an antiphage defense mechanism, where it senses a yet undefined viral cue and synthesizes a common nucleotide second-messenger (cyclic dinucleotides or CDNs) to activate the cyclic-oligonucleotide-based anti-phage signaling system (CBASS), a type of prokaryotic innate defense system [2, 11, 12]. It is unknown whether bacterial CD-NTases are constitutively active in vivo or controlled by several regulatory mechanisms in the eukaryotic cGAS-STING signaling system.

Bacteria have circular genomes comprising of naked DNA supercoiled DNA, which is present in nucleoids (a false nucleus-like structure), and their CD-NTases are encoded in conserved operons in mobile genetic elements (MGEs), such as plasmids [11]. For example, genes encoding identical CD-NTases are often found in specific strains of unrelated bacterial species, reflecting that these genes are members of the “mobilome” [11]. The evolution of eukaryotic linear chromosomes from the prokaryotic circular genome has yet to be well understood [13]. Still, their localization in the eukaryotic true nucleus and evolution of escape mechanisms from the nuclear cGAS recognition, such as the inactivation of nuclear cGAS by several mechanisms and formation of actual chromosomes (DNA + histone bodies forming nucleosomes + chromatin fibers), decreased the chances of host-derived naked DNA in the nucleus, which the free soluble cGAS in the nucleus could recognize. Hence, the nucleus served as a perfect site for the location of sex and autosomal chromosomes to escape from the host’s immune response.

3. Immune Response Differs between Two Sexes

Advances in immune and sex-based studies have further indicated the immune response variation in males and females against different infections and incidence of autoimmunity [14, 15]. Recent coronavirus disease-2019 (COVID-19) pandemic research data has further indicated that females had a lower incidence of severe COVID-19 than age-matched males due to differences in immune response [16]. However, females have a higher incidence of certain autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren’s syndrome (SS). Furthermore, recent trends in cancer incidences have also indicated an increase in different cancers (lung, breast, and colorectal) in reproductive-age women (50 years) [17]. Thus, gender is a critical determinant of immunity, which is not only based on sex hormones but also on neuronal behavior to the stressor, such as infection, antigen, or environmental pollutants. The gender may also influence the expression of different PRRs, such as toll-like receptors 7 and 8 (TLR7 and TLR8), as the TLR7 and TLR8 genes are encoded by the X chromosome, which may escape X chromosome inactivation (XCI), causing TLR7 and TLR8 overexpression (monocytes, macrophages, dendritic cells (DCs), B cells, and CD4+ T cells) in females than males [18, 19]. Thus, altered X chromosome inactivation (XCI) predisposes females toward increased incidence of inflammatory and AIDs [19, 20].

4. Gender-Based Metabolic Differences may also Alter Their Immunometabolic Reprograming (IR)

Every living cell requires energy for its growth, survival, division, and function to maintain homeostasis. The energy generation and expenditure by the cell or host to maintain homeostasis is governed by metabolic processes or metabolism. However, for several years, metabolism was taught in the context of carbohydrate, lipid, and protein metabolism as general, not cell-type specific. Immunological advances have now suggested that immune cell metabolic processes are critical for maintaining immune homeostasis, leading to the development of immunometabolism, and further exploration is needed to advance immune-based precision medicine. Different PRRs’ activation affects IR to control pro-inflammatory immune response differently [21]. Furthermore, the immunometabolism research is complete, undertaking the gender-based immune cell-specific immune response. For example, hormonal and metabolic energy differences in reproductive-age women and men should be critically considered when targeting IR. Vaccination and natural infections have indicated higher protective pro-inflammatory immune responses in reproductive-age women than in age-matched men. Gender-based immunological laboratory data has also supported these findings. Promoters of several innate immunity genes have androgen and estrogen response elements (AREs and EREs), indicating their direct impact on the innate immune response depending on gender. Activation of the innate immune response is the primary determinant of generating the adaptive immune response.

For example, generally, the lipopolysaccharide (LPS) or interferon-γ (IFN-γ) treatment to macrophages induces their polarization to classically activated macrophages (CAMs) or M1 macrophages, generating a pro-inflammatory immune response, but rat testicular macrophages upon LPS/IFN-γ stimulation polarize to macrophages with regulatory phenotypes, like anti-inflammatory M2 macrophages [22]. These testicular macrophages constitutively express interleukin-10 (IL-10), which supports oxidative phosphorylation (OXPHOS) critical for M2 or regulatory macrophage phenotype and function [23, 24, 25]. This finding should further be investigated in ovarian macrophages and gender-based other target organs. The naive macrophage (M0) to M1 and M2 macrophage polarization is critically governed by IR [23]. Furthermore, neutrophils isolated from male mice are more immature and poorly activated than age-matched female mice due to overactive mitochondrial metabolism OXPHOS, modulated by estradiol treatment or its circulating level [26]. Human studies have further supported this finding that the phenotypic and functional differences between adult males and females are hormone-derived, governing their immunometabolism. Furthermore, neutrophils derived from human females overproduce type 1 IFN stimulated gene (ISG) viperin/Radical S-Adenosyl Methionine Domain Containing 2 (RSAD2) than neutrophils isolated from males upon pro-inflammatory stimulation, indicating testosterone affects neutrophil’s type I/II IFN response [27]. Hence, sex hormones critically regulate immune cell functions through IR regulation, and further exploration of immune-based precision medicine is needed in both sexes.

5. Sex/Gender-Associated Differences in Stress Response may also Impact Immune Response by Affecting IR

Further, females respond differently to stress due to different organization and functional effects, including the release of neurotransmitters exerted by sex hormones on human brains [28, 29]. For example, females show sluggish cortisol feedback on the brain and less or delayed containment of the stress response than males, which can affect the immune system/response differently (Fig. 2) [28, 30, 31]. Whereas, once puberty has completed, male sex hormone levels in healthy men do not fluctuate regularly, but female sex hormone levels fluctuate periodically over a much more extensive range than men (Fig. 2). Furthermore acute immune response to stress is well documented in adults [32]. Moreover, there we go for neuroimmunology, which can lead to endoneuroimmunology (endocrine control of neuroimmunology) to study the impact of sex hormones on neuroimmunology. Therefore, pre-existing stress that can be anxiety disorders or disease (cancer or infection)-associated stress can impact energy metabolism, including immunometabolism or IR, differently in females than men (Fig. 2). For example, immunometabolism or IR is critical in cancer pathogenesis and tumor immunity or immune microenvironment [33]. Furthermore, a gender-based mice study has indicated the protective action of invariant natural killer T (iNKT) cells in male mice during high fat and choline-deficient (HFCD) diet-induced steatohepatitis as compared to females [34]. iNKT cells of male and female mice exhibit noteworthy sex/gender-associated disparities as indicated by the production of pro-inflammatory cytokines, iNKT cell gene expression, and immune cell profiles impacting the steatohepatitis-associated immune response. This further suggests that gender-based hormonal differences impact immune cell functioning and their IR, which needs further exploration to delineate the mechanisms of differential outcomes of different immune-based therapies in two genders.

Furthermore, the clinical trial of the drug lecanemab (a high affinity humanized Immunoglobulin G1 (IgG1) monoclonal antibody against amyloid-beta (Aβ) soluble protofibrils) has shown that it can delay the progression of Alzheimer’s disease (AD) [35]. However, closer investigation of the data by independent researchers indicates that men will be more beneficial to this anti-AD drug than females, despite females comprising 60% of patients with AD-associated dementia [36]. A further study in TgF344-AD (TgAD) female rats low-dose radiation therapy (LD-RT) decreases microglial inflammatory markers associated with AD, which is absent in male rats. Instead, an increased microglial activity in the hippocampus was observed [37, 38]. These studies indicate sex/gender influences the incidence and pathogenesis of diseases, such as cancers, neurodegenerative diseases, and different infections, where the immune system is a critical determinant of the outcome. Efforts are continuously in progress to consider sex/gender-based health disparity issues for strengthening biomedical research data and decreasing public health issues [39, 40]. Hence, it is the right time to consider gender-based immunometabolism/IR, governed by hormonal differences controlling their neuronal behavior and immune response, determining their resistance and susceptibility to diseases like cancers, neurodegenerative diseases, autoimmunity, and infections.

6. Discussion

Evolutionary forces first created the immunologically inert environment for the immune escape of the host’s genetic material (DNA) in the form of chromosomes localized in the nucleus as cGLRs, such as cGAS (evolved more than six hundred MYA before the evolution of sex chromosomes), recognize naked DNA released into the cytosol as a result of nuclear and genotoxic damage. Thus, DNA in the intact chromosome and proteins comprising nucleosomes escape from the innate immune response in the nucleus due to their intact structure and inactive cGAS. Furthermore, evidence has emerged indicating differences in the immune responses between the two sexes to fight against infections, responding to immune-based therapies, and higher incidences of AIDs and increased adverse events to immune-based therapies in reproductive age females than males. Therefore, we must recognize gender-based immune response and IR to design precision medicine for immunological disorders and IMIDs. For example, females generate profound inflammatory immune responses to antigens, infections, and vaccines where immune stimulation is needed. Still, they also exhibit more severe immune-mediated adverse events than men [41, 42]. Nevertheless, they are less potent than men in response to immunosuppressive immunotherapeutics such as anti-tumor necrosis factor-alpha (TNF-α) therapies against RA or ICIs prescribed to melanoma and non-small-cell lung cancer patients [43]. A further study has indicated the inclusion of sex and gender differences (impact immunity and cell cycle signaling events) as a continuous variable may significantly improve cancer immunotherapies depending on the cancer type and transcriptomic index (TI) values [44].

7. Conclusion

Therefore, studies on gender-based cellular and tissue immunometabolism are urgently needed to design better immunotherapies and lower the gender disparity in immune-mediated diseases and therapies. Furthermore, immunometabolism research has seen significant advances in the last ten years that further need the inclusion of sex/gender to demystify hidden mechanisms of diseases and different outcomes of immune-based therapies in two sexes.

References

[1]

Margolis SR, Wilson SC, Vance RE. Evolutionary Origins of cGAS-STING Signaling. Trends in Immunology. 2017; 38: 733–743. https://doi.org/10.1016/j.it.2017.03.004.

[2]

Kumar V, Stewart JH, 4th. cGLRs Join Their Cousins of Pattern Recognition Receptor Family to Regulate Immune Homeostasis. International Journal of Molecular Sciences. 2024; 25: 1828. https://doi.org/10.3390/ijms25031828.

[3]

Flajnik MF, Kasahara M. Origin and evolution of the adaptive immune system: genetic events and selective pressures. Nature Reviews. Genetics. 2010; 11: 47–59. https://doi.org/10.1038/nrg2703.

[4]

Coffing GC, Tittes S, Small ST, Songco-Casey JO, Piscopo DM, Pungor JR, et al. Cephalopod Sex Determination and its Ancient Evolutionary Origin Revealed by Chromosome-level Assembly of the California Two-Spot Octopus. bioRxiv. 2024. (in press) https://doi.org/10.1101/2024.02.21.581452.

[5]

Kumar V. The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA. Frontiers in Immunology. 2021; 11: 624597. https://doi.org/10.3389/fimmu.2020.624597.

[6]

Volkman HE, Cambier S, Gray EE, Stetson DB. Tight nuclear tethering of cGAS is essential for preventing autoreactivity. eLife. 2019; 8: e47491. https://doi.org/10.7554/eLife.47491.

[7]

Pathare GR, Decout A, Glück S, Cavadini S, Makasheva K, Hovius R, et al. Structural mechanism of cGAS inhibition by the nucleosome. Nature. 2020; 587: 668–672. https://doi.org/10.1038/s41586-020-2750-6.

[8]

Michalski S, de Oliveira Mann CC, Stafford CA, Witte G, Bartho J, Lammens K, et al. Structural basis for sequestration and autoinhibition of cGAS by chromatin. Nature. 2020; 587: 678–682. https://doi.org/10.1038/s41586-020-2748-0.

[9]

Xu P, Liu Y, Liu C, Guey B, Li L, Melenec P, et al. The CRL5-SPSB3 ubiquitin ligase targets nuclear cGAS for degradation. Nature. 2024; 627: 873–879. https://doi.org/10.1038/s41586-024-07112-w.

[10]

Wu Y, Song K, Hao W, Li J, Wang L, Li S. Nuclear soluble cGAS senses double-stranded DNA virus infection. Communications Biology. 2022; 5: 433. https://doi.org/10.1038/s42003-022-03400-1.

[11]

Whiteley AT, Eaglesham JB, de Oliveira Mann CC, Morehouse BR, Lowey B, Nieminen EA, et al. Bacterial cGAS-like enzymes synthesize diverse nucleotide signals. Nature. 2019; 567: 194–199. https://doi.org/10.1038/s41586-019-0953-5.

[12]

Govande AA, Duncan-Lowey B, Eaglesham JB, Whiteley AT, Kranzusch PJ. Molecular basis of CD-NTase nucleotide selection in CBASS anti-phage defense. Cell Reports. 2021; 35: 109206. https://doi.org/10.1016/j.celrep.2021.109206.

[13]

Schubert I. Chromosome evolution. Current Opinion in Plant Biology. 2007; 10: 109–115. https://doi.org/10.1016/j.pbi.2007.01.001.

[14]

Dunn SE, Perry WA, Klein SL. Mechanisms and consequences of sex differences in immune responses. Nature Reviews. Nephrology. 2024; 20: 37–55. https://doi.org/10.1038/s41581-023-00787-w.

[15]

Forsyth KS, Jiwrajka N, Lovell CD, Toothacre NE, Anguera MC. The conneXion between sex and immune responses. Nature Reviews. Immunology. 2024; 24: 487–502. https://doi.org/10.1038/s41577-024-00996-9.

[16]

Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020; 588: 315–320. https://doi.org/10.1038/s41586-020-2700-3.

[17]

Ledford H. Why are so many young people getting cancer? What the data say. Nature. 2024; 627: 258–260. https://doi.org/10.1038/d41586-024-00720-6.

[18]

Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (New York, N.Y.). 2006; 312: 1669–1672. https://doi.org/10.1126/science.1124978.

[19]

Youness A, Cenac C, Faz-López B, Grunenwald S, Barrat FJ, Chaumeil J, et al. TLR8 escapes X chromosome inactivation in human monocytes and CD4+ T cells. Biology of Sex Differences. 2023; 14: 60. https://doi.org/10.1186/s13293-023-00544-5.

[20]

Huret C, Ferrayé L, David A, Mohamed M, Valentin N, Charlotte F, et al. Altered X-chromosome inactivation predisposes to autoimmunity. Science Advances. 2024; 10: eadn6537. https://doi.org/10.1126/sciadv.adn6537.

[21]

Kumar V, Stewart Iv JH. Pattern-Recognition Receptors and Immunometabolic Reprogramming: What We Know and What to Explore. Journal of Innate Immunity. 2024; 16: 295–323. https://doi.org/10.1159/000539278.

[22]

Winnall WR, Muir JA, Hedger MP. Rat resident testicular macrophages have an alternatively activated phenotype and constitutively produce interleukin-10 in vitro. Journal of Leukocyte Biology. 2011; 90: 133–143. https://doi.org/10.1189/jlb.1010557.

[23]

Kumar V. Targeting macrophage immunometabolism: Dawn in the darkness of sepsis. International Immunopharmacology. 2018; 58: 173–185. https://doi.org/10.1016/j.intimp.2018.03.005.

[24]

Ip WKE, Hoshi N, Shouval DS, Snapper S, Medzhitov R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017; 356: 513–519. https://doi.org/10.1126/science.aal3535.

[25]

Bhushan S, Tchatalbachev S, Lu Y, Fröhlich S, Fijak M, Vijayan V, et al. Differential activation of inflammatory pathways in testicular macrophages provides a rationale for their subdued inflammatory capacity. Journal of Immunology. 2015; 194: 5455–5464. https://doi.org/10.4049/jimmunol.1401132.

[26]

Gupta S, Nakabo S, Blanco LP, O’Neil LJ, Wigerblad G, Goel RR, et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. Proceedings of the National Academy of Sciences of the United States of America. 2020; 117: 16481–16491. https://doi.org/10.1073/pnas.2003603117.

[27]

Er-Lukowiak M, Hänzelmann S, Rothe M, Moamenpour DT, Hausmann F, Khatri R, et al. Testosterone affects type I/type II interferon response of neutrophils during hepatic amebiasis. Frontiers in Immunology. 2023; 14: 1279245. https://doi.org/10.3389/fimmu.2023.1279245.

[28]

Verma R, Balhara YPS, Gupta CS. Gender differences in stress response: Role of developmental and biological determinants. Industrial Psychiatry Journal. 2011; 20: 4–10. https://doi.org/10.4103/0972-6748.98407.

[29]

Chaplin TM, Hong K, Bergquist K, Sinha R. Gender differences in response to emotional stress: an assessment across subjective, behavioral, and physiological domains and relations to alcohol craving. Alcoholism, Clinical and Experimental Research. 2008; 32: 1242–1250. https://doi.org/10.1111/j.1530-0277.2008.00679.x.

[30]

Reschke-Hernández AE, Okerstrom KL, Bowles Edwards A, Tranel D. Sex and stress: Men and women show different cortisol responses to psychological stress induced by the Trier social stress test and the Iowa singing social stress test. Journal of Neuroscience Research. 2017; 95: 106–114. https://doi.org/10.1002/jnr.23851.

[31]

Rohleder N, Schommer NC, Hellhammer DH, Engel R, Kirschbaum C. Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosomatic Medicine. 2001; 63: 966–972. https://doi.org/10.1097/00006842-200111000-00016.

[32]

Gabbay V, Ely BA, Vileisis JN, Petrovic Z, Cicvaric A, Asnis GM, et al. Immune and neural response to acute social stress in adolescent humans and rodents. Translational Psychiatry. 2024; 14: 306. https://doi.org/10.1038/s41398-024-03008-5.

[33]

Kumar V, Stewart JH, 4th. Immunometabolic reprogramming, another cancer hallmark. Frontiers in Immunology. 2023; 14: 1125874. https://doi.org/10.3389/fimmu.2023.1125874.

[34]

Cuño-Gómiz C, de Gregorio E, Tutusaus A, Rider P, Andrés-Sánchez N, Colell A, et al. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice. Biology of Sex Differences. 2023; 14: 85. https://doi.org/10.1186/s13293-023-00569-w.

[35]

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. The New England Journal of Medicine. 2023; 388: 9–21. https://doi.org/10.1056/NEJMoa2212948.

[36]

Buckley RF, Gong J, Woodward M. A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials. JAMA Neurology. 2023; 80: 769–770. https://doi.org/10.1001/jamaneurol.2023.1059.

[37]

Ceyzériat K, Jaques E, Gloria Y, Badina A, Millet P, Koutsouvelis N, et al. Low-Dose Radiation Therapy Impacts Microglial Inflammatory Response without Modulating Amyloid Load in Female TgF344-AD Rats. Journal of Alzheimer’s Disease: JAD. 2024; 98: 1001–1016. https://doi.org/10.3233/JAD-231153.

[38]

Ceyzériat K, Zilli T, Fall AB, Millet P, Koutsouvelis N, Dipasquale G, et al. Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model. Neurobiology of Aging. 2021; 103: 117–127. https://doi.org/10.1016/j.neurobiolaging.2021.03.008.

[39]

Arnold AP, Klein SL, McCarthy MM, Mogil JS. Male-female comparisons are powerful in biomedical research - don’t abandon them. Nature. 2024; 629: 37–40. https://doi.org/10.1038/d41586-024-01205-2.

[40]

Haupt S, Carcel C, Norton R. Neglecting sex and gender in research is a public-health risk. Nature. 2024; 629: 527–530. https://doi.org/10.1038/d41586-024-01372-2.

[41]

St Clair LA, Chaulagain S, Klein SL, Benn CS, Flanagan KL. Sex-Differential and Non-specific Effects of Vaccines Over the Life Course. Current Topics in Microbiology and Immunology. 2023; 441: 225–251. https://doi.org/10.1007/978-3-031-35139-6_9.

[42]

Klein SL, Flanagan KL. Sex differences in immune responses. Nature Reviews. Immunology. 2016; 16: 626–638. https://doi.org/10.1038/nri.2016.90.

[43]

Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biology of Sex Differences. 2020; 11: 24. https://doi.org/10.1186/s13293-020-00301-y.

[44]

Yang W, Rubin JB. Treating sex and gender differences as a continuous variable can improve precision cancer treatments. Biology of Sex Differences. 2024; 15: 35. https://doi.org/10.1186/s13293-024-00607-1.

PDF (1549KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/